Florida Panthers Even Stanley Cup Final Series with Edmonton Oilers
ByAinvest
Saturday, Jun 7, 2025 12:58 am ET1min read
IMMX--
NXC-201 demonstrated a strong safety profile, with no neurotoxicity and only low-grade cytokine release syndrome observed. The therapy also improved cardiac and renal functions in all patients, suggesting significant clinical benefits [1, 2].
Immix Biopharma plans to submit a Biologics License Application (BLA) for FDA approval following the successful trial results. The company is preparing for a Key Opinion Leader (KOL) event to discuss the implications of these findings on Tuesday, June 3, 2025, at 3:00 pm ET [1, 2].
The trial involved ten patients and met its primary endpoint with a CR rate of 70%. No relapses have been recorded to date, indicating the potential of NXC-201 as a viable treatment option for this severe condition. The results underscore the therapy's efficacy and safety profile, positioning it favorably in a market with limited FDA-approved agents [1, 2].
Investors and financial professionals should closely monitor Immix Biopharma's progress as it moves towards FDA approval and potential commercialization of NXC-201. The company's stock has seen recent insider and institutional activity, suggesting interest in the company's prospects [1, 2].
References:
[1] https://finance.yahoo.com/news/h-c-wainwright-reiterates-buy-203346352.html
[2] https://www.nasdaq.com/articles/immix-biopharma-reports-70-complete-response-rate-nxc-201-phase-1-2-al-amyloidosis-trial
TOI--
Immix Biopharma's NXC-201 achieved a 70% complete response rate in its NEXICART-2 Phase 1/2 trial for relapsed/refractory AL Amyloidosis. The therapy demonstrated a strong safety profile with no neurotoxicity and improved cardiac and renal functions in all patients. Immix Biopharma plans to submit a Biologics License Application for FDA approval.
Immix Biopharma, Inc. (NASDAQ:IMMX) has reported promising results from its NEXICART-2 Phase 1/2 clinical trial of NXC-201, a cell therapy for relapsed/refractory AL amyloidosis. The trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025), achieved a 70% complete response (CR) rate, surpassing the typical CR rate of less than 10% for existing treatments [1, 2].NXC-201 demonstrated a strong safety profile, with no neurotoxicity and only low-grade cytokine release syndrome observed. The therapy also improved cardiac and renal functions in all patients, suggesting significant clinical benefits [1, 2].
Immix Biopharma plans to submit a Biologics License Application (BLA) for FDA approval following the successful trial results. The company is preparing for a Key Opinion Leader (KOL) event to discuss the implications of these findings on Tuesday, June 3, 2025, at 3:00 pm ET [1, 2].
The trial involved ten patients and met its primary endpoint with a CR rate of 70%. No relapses have been recorded to date, indicating the potential of NXC-201 as a viable treatment option for this severe condition. The results underscore the therapy's efficacy and safety profile, positioning it favorably in a market with limited FDA-approved agents [1, 2].
Investors and financial professionals should closely monitor Immix Biopharma's progress as it moves towards FDA approval and potential commercialization of NXC-201. The company's stock has seen recent insider and institutional activity, suggesting interest in the company's prospects [1, 2].
References:
[1] https://finance.yahoo.com/news/h-c-wainwright-reiterates-buy-203346352.html
[2] https://www.nasdaq.com/articles/immix-biopharma-reports-70-complete-response-rate-nxc-201-phase-1-2-al-amyloidosis-trial
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet